Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

Norman E. Lepor, Stacey B. Gross, William L. Daley, Bruce A. Samuels, Michael J. Rizzo, Sean P. Luko, Ann Hickey, Neil A. Buchbinder, Tasneem Z. Naqvi

Research output: Contribution to journalArticle

28 Scopus citations
Original languageEnglish (US)
Pages (from-to)107-110
Number of pages4
JournalAmerican Journal of Cardiology
Volume86
Issue number1
DOIs
StatePublished - Jul 1 2000

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lepor, N. E., Gross, S. B., Daley, W. L., Samuels, B. A., Rizzo, M. J., Luko, S. P., Hickey, A., Buchbinder, N. A., & Naqvi, T. Z. (2000). Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. American Journal of Cardiology, 86(1), 107-110. https://doi.org/10.1016/S0002-9149(00)00840-7